We purchase foreign-made special skeleton compounds made with the focus on druggability and diversity based on chemoinformatic and molecular modeling skills of experts to secure compound diversity more efficiently, when it is difficult to secure a sufficient amount through entrustment. In 2014, for example, we secured 72,000 compounds like this and use them in biological activity tests. We plan to rely on outsourcing, including international CROs, to secure wider diversity in compounds owned by us, starting in 2016. As of the end of April 2016, KCB owns 430,000 compounds and plans to continue to expand the chemical library of compounds featuring diversity, druggability, and uniqueness for development of top-valued new drugs.
- The information on all compounds purchased by us can be retrieved from the homepage of KCB.